Cancer immunotherapy has revolutionized treatment strategies, particularly with immune checkpoint blockade (ICB) therapy, which targets the PD-1/PD-L1 pathway. However, the clinical efficacy of anti-PD-1/PD-L1 monoclonal antibodies (mAbs) remains limited due to low response rates, immune resistance, and high costs.
In this study, researchers developed a novel peptide-based nanoparticle, TPM1, designed to bind PD-L1 on tumor cell membranes and transform into fibrillar networks. This transformation aggregates both bound and unbound PD-L1 proteins, effectively blocking the PD-1/PD-L1 pathway and enhancing T-cell activation against tumors.
Mechanism of Action
1. PD-L1 Binding and Fibrillar Transformation
- TPM1 binds specifically to PD-L1 proteins on tumor cells.
- Once bound, TPM1 undergoes self-assembly into fibrillar networks, which trap and aggregate PD-L1 proteins.
- This process inhibits the PD-1/PD-L1 interaction, leading to reduced immune suppression.
2. Prolonged Tumor Retention
- TPM1 remains at the tumor site for over 7 days, unlike traditional anti-PD-L1 antibodies that degrade quickly.
- This prolonged retention enhances immunotherapy effectiveness.
3. Enhanced T-cell Activation
- By blocking PD-L1, TPM1 reactivates CD8+ T cells in the tumor microenvironment.
- In mouse models, this led to significant tumor reduction in breast cancer and lung cancer.
Experimental Results
1. In Vitro Studies
- Western blot and flow cytometry confirmed that TPM1 binds strongly to PD-L1-expressing tumor cells.
- Microscopy imaging showed fibrillar transformation of TPM1 on the tumor cell membrane.
- Cell viability assays demonstrated that TPM1 does not harm normal cells but effectively disrupts tumor cells when combined with T cells.
2. In Vivo Mouse Models
- TPM1 treatment led to tumor size reduction in breast cancer (4T1) and lung cancer (LLC) models.
- Increased CD8+ T cell infiltration was observed, confirming enhanced immune response.
- Survival rates significantly improved compared to untreated or anti-PD-L1 antibody-treated mice.
3. Pharmacokinetics and Safety
- TPM1 nanoparticles demonstrated long circulation time and preferential accumulation at tumor sites.
- No significant toxicity was observed in major organs such as the heart, liver, and kidneys.
- Blood tests confirmed that TPM1 does not cause immune-related adverse events.
Conclusion
This study demonstrates that TPM1 nanoparticles represent a promising new approach to cancer immunotherapy by:
✔Blocking PD-L1 activity through fibrillar network formation.
✔Enhancing CD8+ T cell-mediated tumor suppression.
✔Prolonging tumor retention for sustained therapeutic effects.
With further research, TPM1 could provide a powerful alternative to traditional immune checkpoint inhibitors, potentially improving treatment outcomes for various solid tumors.
Reference : https://www.nature.com/articles/s41467-024-54081-9